--- title: "Lifecore Biomedical, Inc. (LFCR.US)" type: "Symbol" locale: "en" url: "https://longbridge.com/en/quote/LFCR.US.md" symbol: "LFCR.US" name: "Lifecore Biomedical, Inc." industry: "Life Sciences Tools and Services" datetime: "2026-05-20T02:59:06.422Z" locales: - [en](https://longbridge.com/en/quote/LFCR.US.md) - [zh-CN](https://longbridge.com/zh-CN/quote/LFCR.US.md) - [zh-HK](https://longbridge.com/zh-HK/quote/LFCR.US.md) --- # Lifecore Biomedical, Inc. (LFCR.US) ## Company Overview Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities. The company also manufactures and sells pharmaceutical-grade hyaluronic acid in bulk form, as well as for use in formulated and filled syringes and vials for injectable products used in treating various medical conditions and procedures, including ophthalmic and orthopedic applications. In addition, it offers product development services, including analytical method development and validation, formulation development, sterile filtration, process scale-up, pilot studies, stability studies, process validation, and materials production for clinical studies. | Item | Detail | |------|--------| | Industry | Life Sciences Tools and Services | | Exchange | US Market | | Website | [www.lifecore.com](https://www.lifecore.com) | ## Key Drivers > *AI-analyzed key factors driving this stock's performance* ## Longbridge Financial Score™: D > *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge* > Updated: 2026-05-19T04:30:13.000Z **Overall: D (0.78)** **Industry**: Life Sciences Tools and Services | Metric | Value | |--------|-------| | Industry Ranking | 0 / 59 | | Industry Median | C | | Industry Average | C | - **Style**: Value - Stocks where the company's main business is in a mature stage. - **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns. **Multi Score**: D #### Style Score Score: | Indicator | Value | Rating | |-----------|-------|--------| | Revenue YoY | 0.00% | | | Net Profit YoY | 0.00% | | | P/B Ratio | -5.78 | | | Dividend Ratio | 0.00% | | #### Size Score Score: | Indicator | Value | Rating | |-----------|-------|--------| | Market Cap | 164291202.66 | | | Revenue | 129464593.00 | | #### Multi Score Score: D | Indicator | Value | Rating | |-----------|-------|--------| | ROE | 0.00% | D | | Profit Margin | -23.78% | E | | Gross Margin | 31.37% | C | | Revenue YoY | 0.94% | C | | Net Profit YoY | -387.22% | E | | Total Assets YoY | -8.58% | E | | Net Assets YoY | -36.81% | E | | Cash Flow Margin | -36.42% | E | | OCF YoY | 0.94% | C | | Turnover | 0.00 | E | | Gearing Ratio | 85.33% | E | ```chart-data:radar { "title": "Longbridge Financial Score - Lifecore Biomedical, Inc.", "chart_type": "radar", "dimensions": [ { "name": "Style Score", "grade": "", "indicators": [ { "name": "Revenue YoY", "value": "0.00%", "rating": "" }, { "name": "Net Profit YoY", "value": "0.00%", "rating": "" }, { "name": "P/B Ratio", "value": "-5.78", "rating": "" }, { "name": "Dividend Ratio", "value": "0.00%", "rating": "" } ] }, { "name": "Size Score", "grade": "", "indicators": [ { "name": "Market Cap", "value": "164291202.66", "rating": "" }, { "name": "Revenue", "value": "129464593.00", "rating": "" } ] }, { "name": "Multi Score", "grade": "D", "indicators": [ { "name": "ROE", "value": "0.00%", "rating": "D" }, { "name": "Profit Margin", "value": "-23.78%", "rating": "E" }, { "name": "Gross Margin", "value": "31.37%", "rating": "C" }, { "name": "Revenue YoY", "value": "0.94%", "rating": "C" }, { "name": "Net Profit YoY", "value": "-387.22%", "rating": "E" }, { "name": "Total Assets YoY", "value": "-8.58%", "rating": "E" }, { "name": "Net Assets YoY", "value": "-36.81%", "rating": "E" }, { "name": "Cash Flow Margin", "value": "-36.42%", "rating": "E" }, { "name": "OCF YoY", "value": "0.94%", "rating": "C" }, { "name": "Turnover", "value": "0.00", "rating": "E" }, { "name": "Gearing Ratio", "value": "85.33%", "rating": "E" } ] } ] } ``` ## Valuation Analysis | Metric | Current | Industry Ranking | High | Median | Low | |--------|---------|-----------------|------|--------|-----| | PE (TTM) | -3.70 | 37/59 | - | - | - | | PB | -5.78 | 57/59 | 217.06 | 197.69 | 123.92 | | PS (TTM) | 1.27 | 11/59 | 2.28 | 2.10 | 1.90 | | Dividend Yield | 0.00% | - | - | - | - | ## Peer Comparison | Rank | Name | Profit | Growth | Operation | Security | Cash | Rating | | --- | --- | --- | --- | --- | --- | --- | --- | | 01 | ChromaDex (CDXC.US) | A | A | A | B | A | A | | 02 | Agilent Tech (A.US) | A | C | B | C | C | B | | 03 | West Pharmaceutical (WST.US) | B | B | B | B | B | B | | 04 | Illumina (ILMN.US) | A | C | B | D | C | B | | 05 | WuXi Biologics (WXXWY.US) | B | B | C | A | B | B | ## Institutional View ### Analyst Rating Distribution > As of 2026-05-12T04:00:00.000Z Total Analysts: **5** | Rating | Count | Percentage | |--------|-------|-----------| | Buy | 2 | 40% | | Overweight | 1 | 20% | | Hold | 2 | 40% | ### Target Price Forecast | Metric | Price | |--------|-------| | Current Price | 4.38 | | Highest Target | 9.00 | | Lowest Target | 5.00 | ## References - [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/LFCR.US/overview.md) - [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/LFCR.US/norm.md) - [Related News](https://longbridge.com/en/quote/LFCR.US/news.md) - [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/LFCR.US/filings.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**